Acetaminophen + Ibuprofen for Patent Ductus Arteriosus
Trial Summary
What is the purpose of this trial?
This trial is testing a new combination of ibuprofen and IV acetaminophen to treat a heart problem in very premature babies. These babies often don't respond well to just one drug, so using two drugs together might work better. The goal is to see if this combination is safer and more effective than using ibuprofen alone. Ibuprofen is commonly used to close the ductus arteriosus in premature newborns, and IV acetaminophen has shown effectiveness in similar treatments.
Will I have to stop taking my current medications?
The trial information does not specify whether participants must stop taking their current medications. It is best to discuss this with the trial team or your doctor.
What data supports the effectiveness of the drug combination of acetaminophen and ibuprofen for treating patent ductus arteriosus?
Is the combination of acetaminophen and ibuprofen generally safe for humans?
How does the drug combination of acetaminophen and ibuprofen differ from other treatments for patent ductus arteriosus?
The combination of acetaminophen (paracetamol) and ibuprofen for treating patent ductus arteriosus (PDA) in preterm infants is unique because it aims to improve the closure rate of the ductus arteriosus compared to using ibuprofen alone. While ibuprofen is already effective for PDA, adding acetaminophen may enhance its effectiveness, offering a potentially better treatment option for this condition.1231112
Research Team
Amish Jain, MD PhD
Principal Investigator
MOUNT SINAI HOSPITAL
Eligibility Criteria
This trial is for extremely premature infants (born before 27 weeks) with a heart condition called PDA, where the duct fails to close after birth. Infants must not have had previous PDA treatment, except for indomethacin used to prevent bleeding in the brain. They should also have normal kidney and liver function and an adequate platelet count.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either combination therapy with ibuprofen and acetaminophen or standard monotherapy with ibuprofen for PDA treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment, including respiratory support, NEC, mortality, and BPD severity
Outcome Assessment
Assessment of PDA treatment success and other secondary outcomes
Treatment Details
Interventions
- Acetaminophen Injection
- Ibuprofen
Ibuprofen is already approved in United States, Canada, European Union, Japan, China, Switzerland for the following indications:
- Pain relief
- Fever reduction
- Inflammation
- Pain relief
- Fever reduction
- Inflammation
- Pain relief
- Fever reduction
- Inflammation
- Pain relief
- Fever reduction
- Inflammation
- Pain relief
- Fever reduction
- Inflammation
- Pain relief
- Fever reduction
- Inflammation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mount Sinai Hospital, Canada
Lead Sponsor
John Hunter Hospital
Collaborator
Royal Alexandra Hospital
Collaborator
Centre Hospitalier de l'Universite Laval (CHUL)
Collaborator
Royal North Shore Hospital
Collaborator
Prince of Wales Hospital, Shatin, Hong Kong
Collaborator
Sunnybrook Health Sciences Centre
Collaborator
McMaster Children's Hospital
Collaborator
The Rotunda Hospital
Collaborator